Form 4: Pulse Biosciences Director Laviolette Acquires Stock Options

Paul A. Laviolette, a director of Pulse Biosciences, acquired stock options to purchase 250,000 shares of common stock on August 9, 2024.

Summary

• Paul A. Laviolette, a director at Pulse Biosciences, acquired stock options on August 9, 2024.
• He obtained options to purchase 50,000 shares and 200,000 shares of Pulse Biosciences' common stock.
• The exercise price for both options is $15.65 per share.
• The options expire on August 9, 2034.
• The vesting schedule for the 50,000 share option is one-third on the one-year anniversary of the grant, and the remaining shares vest monthly over two years, contingent on continued service.
• The vesting schedule for the 200,000 share option is one-fourth on the date of the Issuer's next annual meeting of stockholders and the remaining shares will vest on a monthly basis over three years thereafter, subject to the Reporting Person's continued service through each vesting date.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting the grant of stock options. The sentiment is slightly positive as it indicates insider confidence, but it's not a major event.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedules and exercise prices are generally structured to incentivize long-term performance and retention.
• Comparable companies in the medical device space, such as Intuitive Surgical or Stryker, also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates